

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Turnbull, et al.

International App. No.: PCT/US2005/007245

Group Art Unit:

International Filing Date: March 3, 2005

Examiner:

For: ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR
MODULATORS

**Commissioner for Patents
Washington, D.C. 20231**

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☒ A copy of the International Search Report which issued on International Application No. PCT/US2005/007245 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Jennifer L. Fox
Attorney for Appliant
Registration No. 52,218

Date: 1 Sept 06

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-6334
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PR60689USW		INTERNATIONAL APP. NO. PCT/US2005/007245	
				APPLICANT Turnbull et al.			
				INTERNATIONAL FILING DATE 3/3/05		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
		2002/099096	7/25/02	Dalton, et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
		98/22441	5/28/98	PCT			
		98/22493	5/28/98	PCT			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
		F.Z. Galin et al., "Synthesis of N-phenylvaline derivatives under phase transfer catalysis," <u>Russian Journal of Organic Chemistry</u> , V34 N6, 1998, page 899.					
		J. Saravanan et al., "RN-244070-45-5, <u>Indian Drugs</u> ," V36 N3, 1999, pp. 192-195.					
		D.R. Tortolani et al., "A convenient synthesis to N-aryl-substituted 4-piperidones," <u>Organic Letters</u> , V1 N8, 1999, pp. 1261-1262.					
		H.F. Dovey et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>Journal of Neurochemistry</u> , V76, N1, 2001, pp. 173-181.					
		C.S. Dunkley et al., "Synthesis and biological evaluation of a novel phenyl-substituted sydnone series a spotential antitumor agents," <u>Bioorganic & Medicinal Chemistry Letters</u> , V13 N17, 2003, pp. 2899-2901.					
		H. Waga et al., "Synthesis of plant growth substances," <u>Noguku Kenkyu</u> , V. 47, 1959, pp. 111-113.					
		C.B. Das et al., "Polyaniline supported cobalt (II)-salen catalyst;; one -pot synthesis of beta-phenylisoserine derivatives from cinnamoyl amide," <u>Tetrahedron Letters</u> , V38 N16, 1997, pp. 2903-2906.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							